Cargando…
CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice
Bone marrow failure and hematopoietic damage is one of the major consequences of irradiation-induced lethality. There is an immediate need to develop medical countermeasures (MCMs) to combat irradiation-induced lethality. We tested the efficacy of CDX-301, developed by Celldex Therapeutics Inc., in...
Autores principales: | Satyamitra, Merriline, Cary, Lynnette, Dunn, Dylan, Holmes-Hampton, Gregory P., Thomas, Lawrence J., Ghosh, Sanchita P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000413/ https://www.ncbi.nlm.nih.gov/pubmed/32019942 http://dx.doi.org/10.1038/s41598-020-58186-1 |
Ejemplares similares
-
CDX-301 prevents radiation-induced dysregulation of miRNA expression and biogenesis
por: Soni, Dharmendra Kumar, et al.
Publicado: (2022) -
Study logistics that can impact medical countermeasure efficacy testing in mouse models of radiation injury
por: DiCarlo, Andrea L., et al.
Publicado: (2020) -
PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
por: Holmes-Hampton, Gregory P., et al.
Publicado: (2023) -
PrC-210 Protects against Radiation-Induced Hematopoietic and Intestinal Injury in Mice and Reduces Oxidative Stress
por: Kumar, Vidya P., et al.
Publicado: (2023) -
Editorial: Recent advances in radiation medical countermeasures
por: Tichy, Ales, et al.
Publicado: (2022)